Cenegermin

Cenegermin
Clinical data
Trade namesOxervate
Other namesRecombinant human nerve growth factor; rhNGF, cenegermin-bkbj
AHFS/Drugs.comMonograph
MedlinePlusa619001
License data
Pregnancy
category
  • AU: B3
Routes of
administration		Ophthalmic
ATC code
Legal status
Legal status
Identifiers
CAS Number
DrugBank
ChemSpider
  • None
UNII
KEGG
Chemical and physical data
FormulaC583H908N166O173S8
Molar mass13267.15 g·mol−1

Cenegermin, sold under the brand name Oxervate, also known as recombinant human nerve growth factor, is a recombinant form of human nerve growth factor.[4] Cenegermin is a peripherally selective agonist of the tropomyosin receptor kinase A (TrkA) and low-affinity nerve growth factor receptor (p75NTR).[4]

The most common side effects include eye pain and inflammation, increased lacrimation (watery eyes), pain in the eyelid and sensation of a foreign body in the eye.[5]

It was approved for medical use in the European Union in July 2017,[5] and in the United States in 2018.[4][6] The US Food and Drug Administration (FDA) considers it to be a first-in-class medication.[6]

  1. ^ "AusPAR: Cenegermin". Therapeutic Goods Administration (TGA). 23 December 2019. Archived from the original on 1 November 2021. Retrieved 26 August 2020.
  2. ^ "Oxervate APMDS". Therapeutic Goods Administration (TGA). 26 May 2022. Retrieved 10 March 2024.
  3. ^ "Summary Basis of Decision (SBD) for Oxervate". Health Canada. 23 October 2014. Retrieved 29 May 2022.
  4. ^ a b c d "Oxervate- cenegermin-bkbj kit; Oxervate- cenegermin-bkbj solution/ drops". DailyMed. 8 October 2024. Retrieved 26 October 2024.
  5. ^ a b c "Oxervate EPAR". European Medicines Agency (EMA). Retrieved 25 August 2020.
  6. ^ a b New Drug Therapy Approvals 2018 (PDF). U.S. Food and Drug Administration (FDA) (Report). January 2019. Retrieved 16 September 2020.